<div id="readability-page-1"><p>Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the six research firms that are currently  covering the stock, MarketBeat reports. One investment analyst  has rated the stock with a sell rating and five have issued  a buy rating on  the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.75.</p><ul><li>Biotech Breakouts: 3 Stocks With Massive Upside Potential</li></ul><p>A number of equities analysts have recently issued reports on IBRX shares. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of ImmunityBio in a report on Monday. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $8.00 target price on shares of ImmunityBio in a report on Wednesday, September 10th. D. Boral Capital  reaffirmed a &#34;buy&#34; rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Thursday. Finally, Jefferies Financial Group  reissued a &#34;buy&#34; rating on shares of ImmunityBio in a research note on Friday.</p><p><b>Check Out Our Latest Report on ImmunityBio</b></p><h2>ImmunityBio Stock Up 8.9%</h2><ul><li>5 Stocks with Unusually Large Short Interest</li></ul><p>ImmunityBio stock traded up $0.20 during mid-day trading on Friday, reaching $2.39. 16,029,761 shares of the company's stock were exchanged, compared to its average volume of 8,571,170. ImmunityBio has a one year low of $1.83 and a one year high of $4.27. The firm has a market capitalization of $2.35 billion, a PE ratio of -5.79 and a beta of 0.10. The business's fifty day simple moving average is $2.29 and its 200 day simple moving average is $2.53. </p><p>ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to analysts' expectations of $31.88 million.  On average, sell-side analysts forecast that  ImmunityBio will post -0.92 earnings per share for the current year. </p><h2>Institutional Trading of ImmunityBio</h2><ul><li>Analysts see over 50% gains in these 2 mid-cap biotech stocks</li></ul><p>Large investors have recently added to or reduced their stakes in the stock. Slow Capital Inc. bought a new position in  ImmunityBio during the 3rd quarter valued at approximately $25,000.  Truist Financial Corp purchased a new position in shares of  ImmunityBio in the 3rd quarter worth about $27,000.  Swiss Life Asset Management Ltd bought a new position in  ImmunityBio in the 3rd quarter worth about $27,000.  Diversify Advisory Services LLC bought a new position in  ImmunityBio in the 2nd quarter worth about $27,000.  Finally, Financial Enhancement Group LLC purchased a new stake in  ImmunityBio during the 2nd quarter valued at about $28,000. Institutional investors own  8.58% of the company's stock. </p><h2>ImmunityBio Company Profile</h2> (Get Free Report)<p>ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.</p><h2>Read More</h2><ul><li>Five stocks we like better than ImmunityBio</li><li>How to Invest in Small Cap Stocks </li><li>Chewy Stock Just Flashed a Major Buy Signal for 2026</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li><li>Why Invest in High-Yield Dividend Stocks?</li><li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUJSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUJSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ImmunityBio Right Now?</h2><p>Before you consider ImmunityBio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.</p><p>While ImmunityBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBRX

<p>ImmunityBio, Inc. (NASDAQ:IBRX) has received an average "Moderate Buy" rating from six research firms. One analyst rated it "sell," while five rated it "buy." The average 1-year price target is $10.75. Recent reports include a "sell" rating from Weiss Ratings and "buy" ratings from HC Wainwright and D. Boral Capital. The stock rose 8.9% to $2.39, with a market cap of $2.35 billion. Institutional investors own 8.58% of the stock. ImmunityBio develops therapies and vaccines for cancer and infectious diseases.</p>

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages